# Cancer Center Support Grant

> **NIH NIH P30** · UNIVERSITY OF CHICAGO · 2024 · $4,523,619

## Abstract

PROJECT SUMMARY/ABSTRACT - OVERALL
The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) is submitting this competing
renewal application for its Cancer Center Support Grant for Years 49-54. The mission of UCCCC is “to eradicate
cancer through equitable prevention, innovative and collaborative research, compassionate patient care,
inclusive education and dedicated community engagement”. Upon arrival in March 2021 as the new Director,
Kunle Odunsi, MD, PhD provided a vision for the Center that focuses on translation of science into the forefront
of UCCCC’s overall mission. To accomplish this, a new Strategic Plan was launched to guide UCCCC towards
its vision to be a “global center of excellence for inclusive and equitable cancer care, research and discovery
dedicated to cancer eradication”. The plan is organized around the cross-cutting themes of bidirectional
translational cancer science between the domains of the laboratory, the clinic, and the community;
transdisciplinary research programs; and transformation of the cancer burden in the catchment area (CA)
and beyond. The 193 members of the UCCCC are organized into 4 Research Programs: Immunology and
Cancer, Clinical and Experimental Therapeutics, Molecular Mechanisms of Cancer, and Cancer Prevention
and Control. They are supported by 10 Shared Resources and 18 multidisciplinary Disease Teams. Notable
accomplishments during this funding cycle (2018-2022) include: (1) Restructuring leadership by creating two
new AD positions (Diversity, Equity and Inclusion [DEI], and Shared Resources); (2) Recruiting 68 talented
researchers (45 new to the University of Chicago); (3) establishing a new Office for DEI; (4) bolstering the
Offices for Community Outreach and Engagement, Cancer Research Training and Education, Clinical
Protocol and Data Management, and Protocol Review and Monitoring Systems; (5) publishing 3,108 scientific
articles 35% of which in high-impact (≥10) journals; (6) securing $55.4M peer-reviewed funding, with $31.0M
from the NCI; (7) increasing interventional accruals by 15%, with 34% minority treatment accruals in CY22
in our CA; and (8) developing 51 new Investigator Initiated Trials (out of a total of 86 actively open), and 45
FDA INDs; (9) launching several major initiatives including a unique collaboration between UCCCC and
Argonne National Laboratories. The Center is a full member of the National Comprehensive Cancer Network,
Alliance for Clinical Trials in Oncology, the Children’s Oncology Group and participates in NRG Oncology studies
as a LAPS main member. The aims of UCCCC in the next funding period are to: (1) catalyze and conduct
innovative, collaborative cancer research; (2) accelerate the translation of UCCCC member discoveries; (3)
reduce cancer burden and disparities in our CA and accelerate health equity in historically underserved
populations; (4) promote education, training, and mentorship; and (5) integrate DEI throughout the fabric of
the UCCCC. Ins...

## Key facts

- **NIH application ID:** 10845090
- **Project number:** 2P30CA014599-48
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** KUNLE ODUNSI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $4,523,619
- **Award type:** 2
- **Project period:** 1997-09-01 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10845090

## Citation

> US National Institutes of Health, RePORTER application 10845090, Cancer Center Support Grant (2P30CA014599-48). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10845090. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*